Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND placebo AND Metformin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    360 result(s) found for: Diabetes AND placebo AND Metformin. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002605-29 Sponsor Protocol Number: NN2211-3659 Start Date*: 2012-05-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) GB (Completed) HU (Completed) DE (Not Authorised) BE (Completed) ES (Completed) DK (Completed) NO (Completed) SE (Completed) PL (Completed) AT (Completed) FR (Completed) PT (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001752-10 Sponsor Protocol Number: TAK-875_302 Start Date*: 2012-10-30
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004833-40 Sponsor Protocol Number: EFC10518 Start Date*: 2008-05-14
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monoth...
    Medical condition: Type 2 Diabetes patients insufficiently controlled with metformin monotherapy
    Disease: Version SOC Term Classification Code Term Level
    10.1 10067585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005220-33 Sponsor Protocol Number: D1690C00004 Start Date*: 2008-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapaglif...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003731-22 Sponsor Protocol Number: MK-0431A-296 Start Date*: 2020-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004895-48 Sponsor Protocol Number: EMLIN-001 Start Date*: 2015-05-06
    Sponsor Name:Profil Institut für Stoffwechselforschung GmbH
    Full Title: Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients with Type 2 Diabetes Mellitus on Stable Metformin Treatment
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000641-54 Sponsor Protocol Number: 1245.10 Start Date*: 2008-08-28
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind t...
    Medical condition: Typr 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) ES (Completed) DE (Completed) LV (Completed) AT (Completed) SK (Completed) CZ (Completed) HU (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015071-27 Sponsor Protocol Number: 0104-005 Start Date*: 2010-01-19
    Sponsor Name:ActivX Biosciences, Inc.
    Full Title: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once-Daily KRP-104 in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Metformin ...
    Medical condition: Type 2 Diabetes with Inadequate Glycemic Control on Metformin Alone
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-002500-26 Sponsor Protocol Number: EFC10231 Start Date*: 2008-10-13
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A multicenter, double blind, placebo controlled randomized study of the efficacy and safety of two rimonabant/metformin combinations for reducing A1C in the treatment of patients with type 2 diabet...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    11.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000763-23 Sponsor Protocol Number: ANJ900D3501 Start Date*: 2021-12-28
    Sponsor Name:Anji Pharma (US) LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Releas...
    Medical condition: Type 2 Diabetes Mellitus with varying renal function from normal up to CKD3B
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012612-41 Sponsor Protocol Number: D1020C00009 Start Date*: 2009-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group study, with an Optional 2-Month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656...
    Medical condition: Type 2 diabetes mellitus patients on metformin treatment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    12.0 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) LV (Completed) SE (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-007588-26 Sponsor Protocol Number: A7941006 Start Date*: 2008-04-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS ...
    Medical condition: PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON METFORMIN TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004913-93 Sponsor Protocol Number: D1690C00012 Start Date*: 2009-01-23
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Comb...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-004032-48 Sponsor Protocol Number: D6160C00058 Start Date*: 2006-01-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Me...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007335-40 Sponsor Protocol Number: EFC10781 Start Date*: 2009-10-01
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 dia...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    11.1 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) EE (Completed) NL (Completed) CZ (Completed) HU (Completed) DK (Completed) IT (Completed) PL (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003869-17 Sponsor Protocol Number: 0893-005 Start Date*: 2006-09-25
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Me...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.0 10045242 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004035-23 Sponsor Protocol Number: 0431A-0289 Start Date*: 2013-03-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) HU (Completed) DK (Completed) BG (Prematurely Ended) Outside EU/EEA GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005326-19 Sponsor Protocol Number: NN9924-4234 Start Date*: 2016-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001731-24 Sponsor Protocol Number: TAK-875_304 Start Date*: 2012-02-29
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metfor...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001259-37 Sponsor Protocol Number: GS-US-259-0147 Start Date*: 2012-09-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus.
    Medical condition: Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 08:53:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA